We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Proteros Announces New Supervisory Board Appointments

Proteros Announces New Supervisory Board Appointments

Proteros Announces New Supervisory Board Appointments

Proteros Announces New Supervisory Board Appointments

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Proteros Announces New Supervisory Board Appointments"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Proteros biostructures GmbH (Proteros) has announced a new supervisory board composition that is aligned with its growth and development objectives to become the preferred partner of choice for biotechnology and pharmaceutical companies seeking a high quality, reliable partner in drug discovery research services.

Proteros’ platform enables ‘knowledge driven lead engineering’ to accelerate and improve protein structure analysis and structure-based lead discovery. The appointments will add significant pharma and biotech expertise to the company and support the further development of the company into a leading integrated drug discovery services provider.
Mr. David Lemus will assume the role of Chairman for the Board and will lead the Business and Corporate Development committee to identify opportunities for expanding Proteros services and establishing strategic collaborations. Mr. Lemus most recently served as a Member of the Management Board, Executive Vice President and Chief Financial Officer of MorphoSys AG.

After taking the Company public in 1999, Mr. Lemus held responsibility for a variety of areas including corporate development, corporate communications, technical operations and legal. He helped build MorphoSys over the past thirteen years and his contributions were central in the rapid growth of the Company.

Mr. Lemus joined MorphoSys in 1998 from F.Hoffmann-La Roche, where he served as a Controller and Operations Manager of 90 pharmaceutical markets. Prior to this position, he served as a Treasurer of Lindt & Sprungli in Zurich, Switzerland and worked in treasury management at Electrolux AB. Mr. Lemus joined MorphoSys AG in February 1998. Mr. Lemus is a Certified Public Accountant in the U.S.A. and holds an M.S. from the M.I.T. Sloan School of Management.

Prof. Dr. Rainer Metternich is newly appointed as Deputy Chairman of the Board. In addition to his responsibility as Deputy Chair of the Supervisory Board, Prof. Metternich will head the R&D/Lead Discovery committee at Proteros to guide the company as it continues to grow and develop its integrated Lead Discovery services offering.

Prof. Metternich is a Senior Research Executive with over 20 years leadership experience at global pharmaceutical companies. He is currently acting Managing Director, Chief Business Officer and Chief Operating Officer of caprotec bioanalytics GmbH. He was previously Vice President and Basic Research Site Head at Merck & Co in West Point, PA, USA.

Prior to that position, he was Executive Vice President and Member of the Executive Committee at Schering AG in Berlin, and, before this, was Global Senior Chemistry Expert at Novartis in Basel, Switzerland. He earned his doctorate degree in organic chemistry from the University at Marburg, Germany with Professor Reinhard W. Hoffmann, was a postdoctoral fellow at Harvard University with Professor David A. Evans and spent a Sabbatical at the University of California, Berkeley with Professor Paul A. Bartlett.

He is on the Editorial Boards of several leading scientific journals and a member of several Scientific Advisory Boards of academic, private and non-profit research organizations.
Torsten Neuefeind, CEO and founder of Proteros, said “It is important that we anticipate our customer’s needs and have established best practice throughout the organization so that we can continue our rapid growth and maintain our high quality reputation. We are very honoured to have such experienced professionals assist in actively guiding Proteros as we continue to grow our integrated drug discovery services.”